Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. - Bateman RJ; Li Y; McDade EM; Llibre-Guerra JJ; Clifford DB; Atri A; Mills SL; Santacruz AM; Wang G; Supnet C; Benzinger TLS; Gordon BA; et al. (The Lancet. Neurology, 2025)